Access Pharmaceuticals (OTCBB:ACCP) announced Tuesday it has signed an agreement with eMax Health Systems to expand the distribution of the company's MuGard treatment.
Access, a biopharmaceutical company focused on supportive care products and treatments for use in the areas of oncology, diabetes and genetic diseases, will use eMax to further distribute its MuGard product, support its payer outreach programs, and advocate for reimbursement amoung U.S. commercial insurance carriers.
MuGard, which has already received FDA marketing clearance, is a ready-to-use oral wound rinse and coating, developed specifically for the treatment of oral mucositis, a common side effect of radiation and chemotherapy.
Approximately 40% of all patients undergoing chemotherapy and radiotherapy develop oral mucositis, and clinical guidelines for the prevention of oral mucositis recommend the use of a preventitive oral care regimen, like MuGard.
eMax, an independent research and pharmaceutical distribution support system, with its network of over 350 national, regional and local pharmacies, said it will provide support by maximizing patient access to Access' MuGard.
"The positive clinical feedback coupled with its favorable pharmacoeconomic value proposition makes MuGard a very important product to the oncology community," eMax CEO, Julian Casciano said.
"We look forward to providing additional support to ensure favorable MuGard formulary position among U.S. payers, hospitals, and large provider institutions."
“Proactiveinvestors is a leading news organisation and event business with offices in New York, Sydney, Toronto and London. The Company is a publisher and is not registered with the US Securities Exchange Commission or Ontario Securities Commission. Please read our full terms and conditions herehttp://www.proactiveinvestors.com/pages/terms”
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites